Development and Validation of a Clinical Risk Score Predicting the No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction

No abstract is available for this paper.

• Publication year

  2013

• Venue

  The Cardiology

• Publication date

  2013-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000346386PMID 23485798
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No-reflow: again prevention is better than treatment.

  2010cited by this paper
• The Development of a Simple Risk Score to Predict Early Outcome in Severe Acute Acidotic Cardiogenic Pulmonary Edema: The 3CPO Score

  2010cited by this paper
• Myocardial no-reflow in humans.

  2009cited by this paper
• Pathophysiology of the no-reflow phenomenon

  2009cited by this paper
• Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study.

  2009cited by this paper
• Coronary no‐reflow phenomenon: From the experimental laboratory to the cardiac catheterization laboratory

  2008cited by this paper
• Effect of β-Blockers on Endothelial Function During Biological Aging: A Nanotechnological Approach

  2008cited by this paper
• Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction.

  2007cited by this paper
• Time to treatment in primary percutaneous coronary intervention.

  2007cited by this paper
• Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality.

  2007cited by this paper
• Relation between neutrophil counts on admission, microvascular injury, and left ventricular functional recovery in patients with an anterior wall first acute myocardial infarction treated with primary coronary angioplasty.

  2007cited by this paper
• Association of C-reactive protein and myocardial perfusion in patients with ST-elevation acute myocardial infarction.

  2006cited by this paper
• The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury.

  2004cited by this paper
• Impact of Microvascular Dysfunction on Left Ventricular Remodeling and Long-Term Clinical Outcome After Primary Coronary Angioplasty for Acute Myocardial Infarction

  2004cited by this paper
• Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction.

  2003cited by this paper
• Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

  2003cited by this paper
• Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction

  2002cited by this paper
• Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction.

  2001cited by this paper
• Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia.

  2001cited by this paper
• Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic.

  2000cited by this paper
• Ischemia-Reperfusion Injury at the Microvascular Level: Treatment by Endothelin A–Selective Antagonist and Evaluation by Myocardial Contrast Echocardiography

  2000cited by this paper
• How should age affect management of acute myocardial infarction? A prospective cohort study.

  1999cited by this paper
• Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group.

  1998cited by this paper
• Usefulness of the Killip classification for early risk stratification of patients with acute myocardial infarction in the 1990s compared with those treated in the 1980s. Israeli Thrombolytic Survey Group and the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group.

  1997cited by this paper
• Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction.

  1996cited by this paper
• Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.

  1994cited by this paper
• The thrombolysis in myocardial infarction (TIMI) trial.

  1985cited by this paper

• A nomogram for predicting intraoperative risk during primary percutaneous coronary intervention based on rapidly obtained data from ST-segment elevation myocardial infarction patients.

  2026cites this paper
• Bibliometric analysis of the no-reflow in ST-segment elevation myocardial infarction patients post-percutaneous coronary intervention: unveiling research trends, collaborative networks, and therapies

  2025cites this paper
• No-Reflow Prediction in Acute Coronary Syndrome During Percutaneous Coronary Intervention: The NORPACS Risk Score

  2024cites this paper
• Predicting the no-reflow phenomenon in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a systematic review of clinical prediction models

  2024cites this paper
• Hospital In Home: Evaluating Need and Readiness for Implementation (HENRI) in the Department of Veterans Affairs: protocol for a mixed-methods evaluation and participatory implementation planning study

  2022cites this paper
• A nomogram risk prediction model for no-reflow after primary percutaneous coronary intervention based on rapidly accessible patient data among patients with ST-segment elevation myocardial infarction and its relationship with prognosis

  2022cites this paper
• Development and Validation of a Novel Risk Stratification Model for Slow-Flow/No-Reflow During Primary Percutaneous Coronary Intervention (the RK-SF/NR Score).

  2022cites this paper
• Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy.

  2022cites this paper
• A nomogram for predicting the risk of no-reflow after primary percutaneous coronary intervention in elderly patients with ST-segment elevation myocardial infarction

  2021cites this paper
• Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction

  2020influential citation
• Platelet/lymphocyte ratio for prediction of no-reflow phenomenon in ST-elevation myocardial infarction managed with primary percutaneous coronary intervention

  2020cites this paper
• Protective effect of Danhong injection in patients with acute myocardial infarction at a high risk of no-reflow during primary percutaneous coronary intervention

  2019cites this paper
• Untapped potential of multicenter studies: a review of cardiovascular risk prediction models revealed inappropriate analyses and wide variation in reporting

  2019cites this paper
• Shock Index on Admission Is Associated with Coronary Slow/No Reflow in Patients with Acute Myocardial Infarction Undergoing Emergent Percutaneous Coronary Intervention

  2019cites this paper
• Efficacy of liraglutide intervention in myocardial infarction

  2018cites this paper
• Clinical significance of dynamic changes in hs-CRP and ADAMTS13 levels in the blood serum of patients with no-reflow after PCI operation.

  2016cites this paper
• Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.

  2016cites this paper
• Clinical effect of preoperative high-dose atorvastatin against no-reflow after PCI

  2016cites this paper
• Adaptive logistic group Lasso method for predicting the no-reflow among the multiple types of high-dimensional variables with missing data

  2016cites this paper
• Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  2015cites this paper
• Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction

  2015cites this paper
• Predicting coronary no-reflow in patients with acute ST-segment elevation myocardial infarction using Bayesian approaches

  2014cites this paper
• The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality

  2014cites this paper
• ST elevation myocardial infarction: recent advances and updates.

  2014cites this paper
• Predicting Coronary No-Reflow in Patients with Acute Myocardial Infarction

  2013cites this paper